Combination of | |
---|---|
Taurolidine | Thiadiazinane antimicrobial |
Heparin | Anti-coagulant |
Clinical data | |
Trade names | Defencath |
AHFS/ Drugs.com | Defencath |
License data | |
Routes of administration | Intraluminal |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Taurolidine/heparin, sold under the brand name Defencath, is a fixed-dose combination catheter lock solution used for central venous catheter instillation. [1] [2] It contains taurolidine, a thiadiazinane antimicrobial; and heparin, an anti-coagulant. Its use is limited to people with kidney failure receiving chronic hemodialysis through a central venous catheter. [1] [2]
The most frequently reported adverse reactions include hemodialysis catheter malfunction, hemorrhage/bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia. [2]
Taurolidine/heparin was approved for medical use in the United States in November 2023. [2] [3] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [4]
Taurolidine/heparin is indicated to reduce catheter-related bloodstream infections in adults with kidney failure who are receiving chronic hemodialysis through a central venous catheter. [1] [2] [5] It is indicated in this limited and specific patient population. [1] [2]
Taurolidine/heparin was studied in a single, randomized, active-controlled phase III clinical trial. [2] In this trial, taurolidine/heparin delayed the time it took to acquire a catheter related bloodstream infection. [2] Taurolidine/heparin demonstrated a 71% risk reduction in catheter related bloodstream infections versus the heparin comparator arm (95% confidence interval for risk reduction: 38% to 86%; p value = 0.0006). [2]
Combination of | |
---|---|
Taurolidine | Thiadiazinane antimicrobial |
Heparin | Anti-coagulant |
Clinical data | |
Trade names | Defencath |
AHFS/ Drugs.com | Defencath |
License data | |
Routes of administration | Intraluminal |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Taurolidine/heparin, sold under the brand name Defencath, is a fixed-dose combination catheter lock solution used for central venous catheter instillation. [1] [2] It contains taurolidine, a thiadiazinane antimicrobial; and heparin, an anti-coagulant. Its use is limited to people with kidney failure receiving chronic hemodialysis through a central venous catheter. [1] [2]
The most frequently reported adverse reactions include hemodialysis catheter malfunction, hemorrhage/bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia. [2]
Taurolidine/heparin was approved for medical use in the United States in November 2023. [2] [3] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [4]
Taurolidine/heparin is indicated to reduce catheter-related bloodstream infections in adults with kidney failure who are receiving chronic hemodialysis through a central venous catheter. [1] [2] [5] It is indicated in this limited and specific patient population. [1] [2]
Taurolidine/heparin was studied in a single, randomized, active-controlled phase III clinical trial. [2] In this trial, taurolidine/heparin delayed the time it took to acquire a catheter related bloodstream infection. [2] Taurolidine/heparin demonstrated a 71% risk reduction in catheter related bloodstream infections versus the heparin comparator arm (95% confidence interval for risk reduction: 38% to 86%; p value = 0.0006). [2]